Ruby Wasti
Boehringer Ingelheim (Brazil)(BR)Boehringer Ingelheim (France)(FR)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Phagocytosis and Immune Regulation, Cancer Research and Treatments, Cancer Immunotherapy and Biomarkers, Peptidase Inhibition and Analysis
Most-Cited Works
- → Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment(2018)2,074 cited
- → Pyrazinoindolone inhibitors of MAPKAP-K2(2007)54 cited
- The oxidase activity of vascular adhesion protein-1 (VAP-1) is essential for function.(2013)
- → Single-cell Map of Diverse Immune Phenotypes Driven by the Tumor Microenvironment(2017)23 cited
- → Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response(2024)12 cited
- → 902 Comprehensive multi-omics meta-analysis of pancreatic cancer mouse models and human PDAC data sets identifies unique cancer-associated fibroblast subsets(2021)
- → Supplementary Table 4 from Reshaping the Tumor Microenvironment of KRAS<sup>G12D</sup> Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response(2024)
- → Data from Reshaping the Tumor Microenvironment of KRAS<sup>G12D</sup> Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response(2024)
- → Supplementary Figure 4 from Reshaping the Tumor Microenvironment of KRAS<sup>G12D</sup> Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response(2024)
- → FIGURE 1 from Reshaping the Tumor Microenvironment of KRAS<sup>G12D</sup> Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response(2024)